Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

Higher levels of retinol-binding protein 4 are found in people with alopecia areata, but these levels don't relate to how severe the condition is.

The Spanish HSS-29 scale effectively measures changes in life quality due to female-pattern hair loss.

Choosing the right tools is crucial for accurately measuring lupus activity and damage.

SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe side effects.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.

SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe symptoms and organ damage in mice.

The Facial Psoriasis Log-based Area and Severity Index is a more effective way to measure improvements in facial psoriasis than the traditional method.

Psoriasis patients experience moderate functional impairment related to disease severity and less satisfaction.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

A woman with Rhupus and Rowell syndrome was treated successfully with medication adjustments.

Pityriasis rubra pilaris significantly worsens quality of life more than many other health conditions.

New tools and criteria have been developed to better assess and treat pediatric lupus.

The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.

Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.

Patients with skin diseases rated psychological effects as most impactful, needing a treatment approach that addresses both mind and body.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

The facial aging scale is a reliable tool for assessing skin aging and treatment effects.

A new tool helps lupus patients and doctors better track symptoms and quality of life.

Wearing wigs or hairpieces improves self-esteem, adaptability, and competence in women with alopecia areata.

The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.

Hair transplantation significantly improves quality of life and self-esteem in men with hair loss.

The Spanish version of the Hair Specific Skindex-29 scale is a reliable and valid way to measure the impact of hair loss on women's quality of life.